Paricalcitol improves the inflammatory status of hemodialysis patients. PAF is a strong inflammatory mediator which is produced during hemodialysis. We studied the effects of paricalcitol on PAF and other inflammatory mediators implicated in chronic kidney disease (CKD).
Methods
We examined the in vitro effects of paricalcitol on PAF/thrombin-induced aggregation as well as on the activities of PAF-basic metabolic enzymes, lyso-PAF acetyltransferase (Lyso-PAF-AT), DTT-insensitive CDP-choline: 1-alkyl-2-acetyl-sn-glycerol cholinephospho-transferase (PAF-CPT) and PAF-acetylhydrolase (PAF-AH) in blood cells from healthy volunteers.
In addition, the in vivo effects of paricalcitol on the above these enzymes were examined in plasma and blood cells of hemodialysis patients who had not received any type of vitamin D treatment during the last three months before and after receiving paricalcitol for a month. Finally, IL-12p70, IL-1β, IL-6, IL-8 and TNF-α were measured.
Results
Paricalcitol inhibited in vitro PAF/thrombin-induced platelet aggregation and the inhibitory effect was comparable with that of PAF/thrombin antagonists. In addition, paricalcitol inhibited in vitro PAF-CPT activity in platelets and leukocytes and increased PAF-AH activity in leukocytes, while much higher concentrations of paricalcitol were needed to inhibit Lyso-PAF-AT activity.
Similarly, in hemodialysis patients, paricalcitol treatment reduced PAF-CPT activity in platelets and leukocytes and increased PAF-AH activity in leukocytes, while it could not influence Lyso-PAF-AT activity. On the other hand, paricalcitol therapy reduced IL-8, IL-1β, and TNF-α.
Conclusions
These results further support the beneficial effects of vitamin D treatment in hemodialysis patients, since it strongly affects PAF/thrombin activities, PAF-metabolism, and IL-8, IL-1β and TNF-α circulating levels.
Del ValleE., NegriA.L., AguirreC., FradingerE., ZanchettaJ.R.Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int.2007; 11(3): 315–321.
2.
UhligK., SarnakM.J., SinghA.K.New approaches to the treatment of calcium and phosphorus abnormalities in patients on hemodialysis. Curr Opin Nephrol Hypertens.2001; 10(6): 793–798.
3.
PilzS., IodiceS., ZittermannA., GrantW.B., GandiniS.Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis.2011; 58(3): 374–382.
4.
Wu-WongJ.R., NakaneM., TraylorL., RuanX., KroegerP.E., TianJ.Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?Curr Opin Investig Drugs.2005; 6(3): 245–254.
5.
PetcheyW.G., JohnsonD.W., IsbelN.M.Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton).2011; 16(4): 351–367.
6.
OgawaT., KyonoA., SatoM., SugimotoH., OtsukaK., NittaK.Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol.2012; 16(5): 779–785.
7.
TengM., WolfM., LowrieE., OfsthunN., LazarusJ.M., ThadhaniR.Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med.2003; 349(5): 446–456.
8.
TettaC., DavidS., BianconeL., CaninoF., CambiV., CamussiG.Role of platelet activating factor in hemodialysis. Kidney Int Suppl.1993; 39: S154–S157.
9.
PericoN., RemuzziG.Role of platelet-activating factor in renal immune injury and proteinuria. Am J Nephrol.1990; 10(Suppl 1): 98–104.
10.
CamussiG., TettaC., BussolinoF., AndresG., TurelloE., BaglioniC.Involvement of cytokines and platelet-activating factor in renal pathology. J Lipid Mediat.1990; 2(suppl): S203–S213.
11.
IatrouC., AfentakisN., AntonopoulouS., AndrikopoulosN., DemopoulosC.A., ZiroyannisP.The production of platelet-activating factor (PAF) during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it?Int J Artif Organs.1995; 18(7): 355–361.
12.
IatrouC., AfentakisN., NomikosT., DinasC., Stavropoulos-GiokasC., AntonopoulouS.Is platelet-activating factor produced during hemodialysis with AN-69 polyacrylonitrile membrane?Nephron.2002; 91(1): 86–93.
13.
DemopoulosC.A., PinckardR.N., HanahanD.J.Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem.1979; 254(19): 9355–9358.
14.
ZimmermanG.A., McIntyreT.M., PrescottS.M., StafforiniD.M.The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med.2002; 30(5)(Suppl): S294–S301.
15.
StafforiniD.M., McIntyreT.M., ZimmermanG.A., PrescottS.M.Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci.2003; 40(6): 643–672.
16.
DemopoulosC.A., KarantonisH.C., AntonopoulouS.Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol.2003; 105(11): 705–716.
17.
SnyderF.Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J.1995; 305(Pt 3): 689–705.
18.
SilversteinD.M.Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol.2009; 24(8): 1445–1452.
19.
CappelliG., DiFeliceA., PerroneS.Which level of cytokine production is critical in haemodialysis?Nephrol Dial Transplant.1998; 13(Suppl 7): 55–60.
20.
StenvinkelP., KettelerM., JohnsonR.J.IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int.2005; 67(4): 1216–1233.
21.
BussolinoF., SironiM., BocchiettoE., MantovaniA.Synthesis of platelet-activating factor by polymorphonuclear neutrophils stimulated with interleukin-8. J Biol Chem.1992; 267(21): 14598–14603.
22.
BussolinoF., CamussiG., TettaC., GarbarinoG., BosiaA., BaglioniC.Selected cytokines promote the synthesis of platelet-activating factor in vascular endothelial cells: comparison between tumor necrosis factor alpha and beta and interleukin-1. J Lipid Mediat.1990; 2(suppl): S15–S22.
23.
NasuK., NaraharaH., MatsuiN., KawanoY., TanakaY., MiyakawaI.Platelet-activating factor stimulates cytokine production by human endometrial stromal cells. Mol Hum Reprod.1999; 5(6): 548–553.
24.
AndressD.L.Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int.2006; 69(1): 33–43.
25.
ChenS.F.1 alpha, 25-Dihydroxyvitamin D3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation. J Steroid Biochem Mol Biol.1995; 52(1): 67–70.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem.1976; 72: 248–254.
28.
TsouprasA.B., FragopoulouE., NomikosT., IatrouC., AntonopoulouS., DemopoulosC.A.Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm.2007; 2007: 27683.
29.
BlighE.G., DyerW.J.A rapid method of total lipid extraction and purification. Can J Biochem Physiol.1959; 37(8): 911–917.
30.
TsouprasA.B., ChiniM., TsogasN.Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?AIDS Res Hum Retroviruses.2008; 24(8): 1079–1086.
31.
AntonopoulouS., DemopoulosC.A., IatrouC., MoustakasG., ZirogiannisP.Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem.1994; 26(9): 1157–1162.
32.
MorganE., VarroR., SepulvedaH.Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol.2004; 110(3): 252–266.
33.
HeuerH.O.Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids.1991; 26(12): 1369–1373.
34.
FletcherJ.R., DiSimoneA.G., EarnestM.A.Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg.1990; 211(3): 312–316.
35.
IzquierdoI., MerlosM., García-RafanellJ.Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc).2003; 39(6): 451–468.
36.
TsantilaN., TsouprasA.B., FragopoulouE., AntonopoulouS., IatrouC., DemopoulosC.A.In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology.2011; 62(3): 209–218.
37.
Agmon-LevinN., BlankM., Zandman-GoddardG.Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis.2011; 70(1): 145–150.
38.
BeerT.M., VennerP.M., RyanC.W.High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol.2006; 135(3): 392–394.
39.
DetopoulouP., NomikosT., FragopoulouE.Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem.2009; 42(1-2): 44–49.
40.
KhovidhunkitW., MemonR.A., ShigenagaJ.K.Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism.1999; 48(12): 1524–1531.
41.
IatrouC., MoustakasG., AntonopoulouS., DemopoulosC.A., ZiroyiannisP.Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron.1996; 72(4): 611–616.
42.
AsanoK., OkamotoS., FukunagaK.Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun.1999; 261(2): 511–514.
43.
PapavasiliouE.C., GouvaC., SiamopoulosK.C., TselepisA.D.Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. Kidney Int.2005; 68(1): 246–255.
44.
PereiraB.J., ShapiroL., KingA.J., FalagasM.E., StromJ.A., DinarelloC.A.Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int.1994; 45(3): 890–896.
45.
StubbsJ.R., IdicullaA., SlusserJ., MenardR., QuarlesL.D.Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol.2010; 21(2): 353–361.
46.
PanichiV., De PietroS., AndreiniB.Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int.1998; 54(5): 1463–1469.
